{"artifact_id":"open_question-cae3f33d-c521-41eb-a129-de88719231be","artifact_type":"open_question","title":"How can Biomarkers, Amyloid, Prevention signals be standardized across cohorts and sites without losing disease-stage sensitivity?","quality_score":0.5,"is_latest":1,"version_number":1,"version_count":1,"debate_count":0,"supports_count":0,"contradicts_count":0,"neutral_count":0,"incoming_by_type":{},"total_incoming":0,"outgoing_by_type":{"derives_from":1,"partial_answer_for":5,"discriminating_experiment":1,"bears_on_question":9},"total_outgoing":16,"quality_trajectory":[{"score":0.5,"at":"2026-04-27T05:25:56.022789-07:00"},{"score":0.5,"at":"2026-04-26T23:44:36.179837-07:00"}],"evidence_balance":0.0,"evidence_certainty":0.0,"total_evidence_items":16,"is_well_supported":false,"is_controversial":false,"is_foundational":false}